Tessera Therapeutics raises $300M in series C round

Tessera Therapeutics Inc. raised over $300 million in a series C financing round.

Investors included a wholly owned subsidiary of Abu Dhabi Investment Authority, Alaska Permanent Fund Corp., Altitude Life Science Ventures, ARTIS Ventures, Cormorant Asset Management LP, Flagship Pioneering, Hanwha General Chemical USA Corp., Longevity Vision Fund, March Capital Venture Management Services LLC, SALT Fund I LP, SoftBank Investment Advisers (UK) Ltd., funds and accounts advised by T. Rowe Price Group Inc., and the company's founder and its existing institutional shareholders.

Biotechnology company Tessera works in the field of genetic medicine using a new approach known as gene writing technology.